← Back to All US Stocks

ARDX Stock Analysis - ARDELYX, INC. AI Rating

ARDX Nasdaq Pharmaceutical Preparations DE CIK: 0001437402
Analysis Date: Mar 20, 2026 | Data as of: 2025-12-31
AI Rating
SELL
82% Confidence

Investment Thesis

Ardelyx exhibits severe operational challenges with massive losses despite 22% revenue growth, indicating poor unit economics and inability to monetize sales effectively. The company faces critical cash burn (-$44M FCF) with only 68M cash reserves against 202.8M long-term debt, creating near-term solvency concerns unless losses narrow significantly.

ARDX Strengths

  • + Strong revenue growth of 22.1% year-over-year demonstrates market demand for products
  • + Solid liquidity position with 4.31x current ratio provides near-term operational flexibility
  • + Positive insider activity with 20 Form 4 filings in last 90 days suggests management confidence

ARDX Risks

  • ! Catastrophic profitability with -15.1% net margin and operating losses of $41M despite $407M revenue indicates fundamental business model problems
  • ! Negative free cash flow of $44M annually is unsustainable; at current burn rate, cash reserves could deplete within 1-2 years without additional financing
  • ! Excessive leverage with 1.21x debt-to-equity ratio and $202.8M long-term debt against $68M cash creates significant refinancing risk
  • ! Deteriorating EPS trend (-52.9% YoY) despite revenue growth signals worsening operational performance
  • ! Negative interest coverage of -17.4x indicates company cannot service debt from operations

Key Metrics to Watch

ARDX Financial Metrics

Revenue
$407.3M
Net Income
$-61.6M
EPS (Diluted)
$-0.26
Free Cash Flow
$-44.0M
Total Assets
$501.6M
Cash Position
$68.0M

ARDX Profitability Ratios

Gross Margin 1.1%
Operating Margin -10.1%
Net Margin -15.1%
ROE -36.9%
ROA -12.3%
FCF Margin -10.8%

ARDX Balance Sheet & Liquidity

Current Ratio
4.31x
Quick Ratio
2.93x
Debt/Equity
1.21x
Debt/Assets
66.7%
Interest Coverage
-17.39x
Long-term Debt
$202.8M

ARDX 5-Year Financial Trend

ARDX 5-year financial data: Year 2021: Revenue $10.1M, Net Income -$94.9M, EPS $-1.47. Year 2022: Revenue $52.2M, Net Income -$94.3M, EPS $-1.05. Year 2023: Revenue $124.5M, Net Income -$158.2M, EPS $-1.52. Year 2024: Revenue $333.6M, Net Income -$67.2M, EPS $-0.42. Year 2025: Revenue $407.3M, Net Income -$66.1M, EPS $-0.30.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: ARDELYX, INC.'s revenue has grown significantly by 3,934% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.30 indicates the company is currently unprofitable.

ARDX Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-10.8%
Free cash flow / Revenue

ARDX Quarterly Performance

Quarterly financial performance data for ARDELYX, INC. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $98.2M -$809.0K $0.00
Q2 2025 $73.2M -$16.5M $-0.07
Q1 2025 $46.0M -$26.5M $-0.11
Q3 2024 $56.4M -$809.0K $0.00
Q2 2024 $22.3M -$16.5M $-0.07
Q1 2024 $11.4M -$26.5M $-0.11
Q3 2023 $5.0M $6.6M $0.03
Q2 2023 $2.5M -$17.1M $-0.08

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

ARDX Capital Allocation

Operating Cash Flow
-$42.5M
Cash generated from operations
Stock Buybacks
$2.0K
Shares repurchased (TTM)
Capital Expenditures
$1.5M
Investment in assets
Dividends
None
No dividend program

ARDX SEC Filings

Access official SEC EDGAR filings for ARDELYX, INC. (CIK: 0001437402)

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2025-12-31 | Powered by Claude AI